Security
4D Molecular Therapeutics, Inc. Common Stock · FDMT
FDMTNASDAQCommon stockCurrentCIK 1650648Updated Oct 21, 2026
Name history
4D Molecular Therapeutics Inc. · through May 12, 20224D Molecular Therapeutics Inc · through Sep 30, 2019
FDMT price & chart
Loading TradingView…
NASDAQ:FDMT on TradingView ↗In the news
4DMT Announces New Employment Inducement Grants ↗
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT News provided by Pomerantz LLP Jan 28, 2025, 12:00 ET Share this article Share to X Share this article Share to X NEW YORK , Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is inves ↗
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT News provided by Pomerantz LLP Jan 21, 2025, 18:10 ET Share this article Share to X Share this article Share to X NEW YORK , Jan. 21, 2025 /PRNewswire/ -- Pomerantz LLP is inves ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 423,982,000Source | 604,028,000Source | 492,615,000Source | 473,637,000Source | 620,117,000Source | 512,905,000Source | 515,729,000Source | 629,884,000Source | 566,711,000Source | 560,384,000Source | 339,891,000Source | 261,846,000Source |
| Property, Plant and Equipment, NetUSD | 16,153,000Source | 19,866,000Source | 12,379,000Source | 17,505,000Source | 18,761,000Source | 13,587,000Source | 18,745,000Source | 19,464,000Source | 14,867,000Source | 19,534,000Source | 20,126,000Source | 22,262,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 48,555,000Source | 187,539,000Source | 70,372,000Source | 77,159,000Source | 189,061,000Source | 72,488,000Source | 133,526,000Source | 275,594,000Source | 60,241,000Source | 149,336,000Source | 249,108,000Source | 52,351,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Assets, CurrentUSD | 312,377,000Source | 510,757,000Source | 382,957,000Source | 303,287,000Source | 552,633,000Source | 405,364,000Source | 332,566,000Source | 535,589,000Source | 413,134,000Source | 434,932,000Source | 296,588,000Source | 220,511,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 7,314,000Source | 8,865,000Source | 17,012,000Source | 10,062,000Source | 10,687,000Source | 14,472,000Source | 11,129,000Source | 9,678,000Source | 10,479,000Source | 10,055,000Source | 8,356,000Source | 6,957,000Source |
| Operating Lease, Right-of-Use AssetUSD | 18,907,000Source | 21,762,000Source | 16,548,000Source | 19,649,000Source | 10,688,000Source | 17,357,000Source | 20,371,000Source | 11,118,000Source | 18,143,000Source | 21,074,000Source | 11,539,000Source | 13,085,000Source |
| Other Assets, NoncurrentUSD | 9,380,000Source | 2,864,000Source | 11,436,000Source | 9,390,000Source | 2,320,000Source | 9,858,000Source | 7,043,000Source | 771,000Source | 9,188,000Source | 4,261,000Source | 684,000Source | 1,080,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 54,999,000Source | 51,080,000Source | 84,956,000Source | 52,747,000Source | 31,777,000Source | 61,069,000Source | 46,006,000Source | 29,323,000Source | 61,047,000Source | 49,778,000Source | 32,062,000Source | 30,509,000Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 5,000Source | 5,000Source | 6,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 6,000Source | 5,000Source | 4,000Source | 3,000Source |
| Retained Earnings (Accumulated Deficit)USD | -735,701,000Source | -526,524,000Source | -858,000,000Source | -678,825,000Source | -482,681,000Source | -785,064,000Source | -624,167,000Source | -447,728,000Source | -716,304,000Source | -576,195,000Source | -415,327,000Source | -314,490,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 671,000Source | 1,079,000Source | -446,000Source | 337,000Source | -293,000Source | -180,000Source | 332,000Source | -109,000Source | 727,000Source | 229,000Source | 16,000Source | -1,196,000Source |
| Stockholders' Equity Attributable to ParentUSD | 368,983,000Source | 552,948,000Source | 407,659,000Source | 420,890,000Source | 588,340,000Source | 451,836,000Source | 469,723,000Source | 600,561,000Source | 505,664,000Source | 510,606,000Source | 307,829,000Source | 231,337,000Source |
| Additional Paid in Capital, Common StockUSD | 1,104,008,000Source | 1,078,388,000Source | 1,266,099,000Source | 1,099,373,000Source | 1,071,309,000Source | 1,237,075,000Source | 1,093,553,000Source | 1,048,393,000Source | 1,221,235,000Source | 1,086,567,000Source | 723,136,000Source | 547,020,000Source |
| Liabilities and EquityUSD | 423,982,000Source | 604,028,000Source | 492,615,000Source | 473,637,000Source | 620,117,000Source | 512,905,000Source | 515,729,000Source | 629,884,000Source | 566,711,000Source | 560,384,000Source | 339,891,000Source | 261,846,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 37,107,000Source | 29,465,000Source | 47,673,000Source | 34,677,000Source | 19,403,000Source | 43,404,000Source | 26,899,000Source | 16,403,000Source | 43,985,000Source | 29,149,000Source | 18,951,000Source | 15,731,000Source |
| Operating Lease, Liability, CurrentUSD | 5,695,000Source | 5,091,000Source | 5,374,000Source | 5,721,000Source | 3,196,000Source | 5,486,000Source | 5,679,000Source | 3,173,000Source | 5,592,000Source | 5,637,000Source | 3,149,000Source | 2,655,000Source |
| Accounts Payable, CurrentUSD | 6,863,000Source | 2,924,000Source | 12,522,000Source | 8,700,000Source | 3,431,000Source | 14,692,000Source | 4,151,000Source | 4,217,000Source | 11,159,000Source | 4,386,000Source | 3,515,000Source | 3,322,000Source |
| Operating Lease, Liability, NoncurrentUSD | 16,568,000Source | 19,743,000Source | 14,256,000Source | 17,356,000Source | 10,460,000Source | 15,049,000Source | 18,174,000Source | 10,998,000Source | 15,821,000Source | 18,969,000Source | 11,522,000Source | 13,469,000Source |
| Other Liabilities, NoncurrentUSD | 144,000Source | 196,000Source | 101,000Source | 161,000Source | 214,000Source | 121,000Source | 177,000Source | 231,000Source | 138,000Source | 193,000Source | 248,000Source | 21,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 24,189,000Source | 21,415,000Source | 25,431,000Source | 19,190,000Source | 12,776,000Source | 22,866,000Source | 16,203,000Source | 9,013,000Source | 26,874,000Source | 18,869,000Source | 12,014,000Source | 8,870,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | 514,000,000Source | — | — | — |
| Long-term Debt, Excluding Current Maturities | — | — | —Source | — | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -68,760,000Source | -47,972,000Source | -140,109,000Source | -160,868,000Source | -100,837,000Source | -107,494,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 4,453,000Source | 6,986,000Source | 22,016,000Source | 26,116,000Source | 19,665,000Source | 17,121,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | — | — | — | 0Source | -47,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 3,533,000Source | -235,000Source | 6,773,000Source | 871,000Source | 896,000Source | -1,638,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -68,125,000Source | -47,758,000Source | -109,082,000Source | -134,585,000Source | -75,792,000Source | -86,685,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 68,888,000Source | 31,948,000Source | -92,973,000Source | -302,437,000Source | 115,717,000Source | -17,050,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 631,000Source | 536,000Source | 3,786,000Source | 2,771,000Source | 11,536,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 11,484,000Source | 0Source | 112,960,000Source | 337,250,000Source | 156,832,000Source | 3,085,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 12,247,000Source | -15,810,000Source | -89,095,000Source | -99,772,000Source | 196,757,000Source | -100,650,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 4,519,000Source | 6,490,000Source | 5,884,000Source | 4,958,000Source | 4,453,000Source | 6,986,000Source | 22,016,000Source | 26,116,000Source | 19,665,000Source | 17,121,000Source |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | — | — | — | — | — | — | — | 514,000,000Source | — | — | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| DepreciationUSD | — | — | 1,300,000Source | 1,200,000Source | 1,300,000Source | 1,300,000Source | 1,300,000Source | 1,300,000Source | 5,200,000Source | 4,800,000Source | 4,400,000Source | 2,400,000Source |
| General and Administrative ExpenseUSD | — | — | 11,837,000Source | 12,651,000Source | 12,524,000Source | 11,520,000Source | 11,687,000Source | 12,936,000Source | 49,060,000Source | 46,579,000Source | 36,494,000Source | 32,908,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Investment Income, InterestUSD | — | — | 4,330,000Source | 7,290,000Source | 4,255,000Source | 4,859,000Source | 4,864,000Source | 5,582,000Source | 19,475,000Source | 27,050,000Source | 12,211,000Source | 2,573,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -56,876,000Source | -43,843,000Source | -72,936,000Source | -54,658,000Source | -68,760,000Source | -47,972,000Source | -140,109,000Source | -160,868,000Source | -100,837,000Source | -107,494,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -56,876,000Source | -43,843,000Source | -72,936,000Source | -54,658,000Source | -68,760,000Source | -47,972,000Source | -140,109,000Source | -160,868,000Source | -100,837,000Source | -107,494,000Source |
| Nonoperating Income (Expense)USD | — | — | 4,309,000Source | 7,289,000Source | 4,089,000Source | 4,798,000Source | 4,860,000Source | 5,649,000Source | 19,438,000Source | 26,973,000Source | 12,030,000Source | 2,538,000Source |
| Operating ExpensesUSD | — | — | 61,275,000Source | 51,135,000Source | 80,806,000Source | 59,471,000Source | 76,667,000Source | 53,635,000Source | 244,756,000Source | 187,878,000Source | 133,590,000Source | 113,161,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -21,000Source | -1,000Source | -166,000Source | -61,000Source | -4,000Source | 67,000Source | -37,000Source | -77,000Source | -181,000Source | -35,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 90,000Source | 3,000Source | 3,781,000Source | 15,000Source | 3,047,000Source | 14,000Source | 85,209,000Source | 37,000Source | 20,723,000Source | 3,129,000Source |
| Operating Income (Loss)USD | — | — | -61,185,000Source | -51,132,000Source | -77,025,000Source | -59,456,000Source | -73,620,000Source | -53,621,000Source | -159,547,000Source | -187,841,000Source | -112,867,000Source | -110,032,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -21,000Source | -1,000Source | -166,000Source | -61,000Source | -4,000Source | 67,000Source | -37,000Source | -77,000Source | -181,000Source | -35,000Source |
| Income Tax Expense (Benefit)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -56,876,000Source | -43,843,000Source | -72,936,000Source | -54,658,000Source | -68,760,000Source | -47,972,000Source | -140,109,000Source | -160,868,000Source | -100,837,000Source | -107,494,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -1.01Source | -0.79Source | -1.04Source | -0.98Source | -1.01Source | -0.86Source | -2.42Source | -2.98Source | -2.58Source | -3.32Source |
| Earnings Per Share, DilutedUSD per share | — | — | -1.01Source | -0.79Source | -1.04Source | -0.98Source | -1.01Source | -0.86Source | -2.42Source | -2.98Source | -2.58Source | -3.32Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 56,126,330Source | 55,554,476Source | 70,272,018Source | 55,927,091Source | 68,064,586Source | 55,744,047Source | 57,930,180Source | 53,943,741Source | 39,130,067Source | 32,351,221Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 56,126,330Source | 55,554,476Source | 70,272,018Source | 55,927,091Source | 68,064,586Source | 55,744,047Source | 57,930,180Source | 53,943,741Source | 39,130,067Source | 32,351,221Source |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 1,269,000Source | 1,051,000Source | 4,694,000Source | 4,653,000Source | 4,204,000Source | 2,403,000Source |
| General and Administrative ExpenseUSD | — | — | 11,837,000Source | 12,651,000Source | 12,524,000Source | 11,520,000Source | 11,687,000Source | 12,936,000Source | 49,060,000Source | 46,579,000Source | 36,494,000Source | 32,908,000Source |
| Investment Income, InterestUSD | — | — | 4,330,000Source | 7,290,000Source | 4,255,000Source | 4,859,000Source | 4,864,000Source | 5,582,000Source | 19,475,000Source | 27,050,000Source | 12,211,000Source | 2,573,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -56,876,000Source | -43,843,000Source | -72,936,000Source | -54,658,000Source | -68,760,000Source | -47,972,000Source | -140,109,000Source | -160,868,000Source | -100,837,000Source | -107,494,000Source |
| Nonoperating Income (Expense)USD | — | — | 4,309,000Source | 7,289,000Source | 4,089,000Source | 4,798,000Source | 4,860,000Source | 5,649,000Source | 19,438,000Source | 26,973,000Source | 12,030,000Source | 2,538,000Source |
| Operating ExpensesUSD | — | — | 61,275,000Source | 51,135,000Source | 80,806,000Source | 59,471,000Source | 76,667,000Source | 53,635,000Source | 244,756,000Source | 187,878,000Source | 133,590,000Source | 113,161,000Source |
Offerings
Registration 333-295650
Filing attachments
fdmt-ex99_1.htm · 8-K · 2026-08-13
EX-99.1 2 fdmt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones • Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027 • 4D-150 4FRONT-1 Phase 3 topline data expected in Q2 2027 • Presented positive 2-year data from 4D-150 PRISM Phase 2b at ASRS, highlighting long-term continuous treatment effect and ongoing favorable safety profile • Plan to initiat…
Read attachment ↗d298087dex44.htm · S-3 · 2026-05-07
Exhibit 4.4 4D MOLECULAR THERAPEUTICS, INC. INDENTURE Dated as of ___________, 20___ [ ] as Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions. 1 Sec…
Read attachment ↗fdmt-ex99_1.htm · 8-K · 2026-05-07
EX-99.1 2 fdmt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones • 4D-150 4FRONT-1 wet AMD Phase 3 randomization complete (N=523); topline data expected in H1 2027 • 4FRONT - 2 enrollment completion expected in H2 2026; topline data expected in H2 2027 • 4D-150 PRISM wet AMD Phase 2b 2-year data expected at a scientific conference in Q3 2026, and SPECTRA DME trial 2-year data expected in H2…
Read attachment ↗fdmt-ex99_1.htm · 8-K · 2026-03-18
EX-99.1 2 fdmt-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones • Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data expected in H1 2027 • PRISM wet AMD Phase 2b 2-year data expected in mid-2026 and SPECTRA DME trial 2-year data in H2 2026 • 4D-15…
Read attachment ↗fdmt-ex4_1.htm · 8-K · 2026-01-26
Exhibit 4.1 4D MOLECULAR THERAPEUTICS, INC. [FORM OF] WARRANT TO PURCHASE SHARES OF COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. CS – [ ] Original Issue Date: January 22, 2026 ─────────────────────────────────────────────────────────────────── 4D Molecular Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered …
Read attachment ↗